Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

• DOI: 10.1210/js.2017-00432
• Publication Date: 2018-02-06T19:06:32Z
• Authors: Tomoko Kobayashi; Shintaro Iwama; Yoshinori Yasuda; Norio Okada; Taku Tsunekawa; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Yoshiaki Morishita; Motomitsu Goto; Hidetaka Suga; Ryoichi Banno; Kenji Yokota; Tetsunari Hase; Masahiro Morise; Naozumi Hashimoto; Masahiko Ando; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
• Keywords: Levothyroxine; Thyroid peroxidase; Thyroglobulin

Immune checkpoint inhibitors, including anti–programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), endocrinopathies. This study examined the incidence endocrine irAEs induced by nivolumab. Sixty-six patients treated with nivolumab at Nagoya University Hospital were prospectively evaluated pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after initiation 24 weeks. Four out 66 developed destructive thyroiditis, three hypothyroidism requiring levothyroxine replacement. The prevalence positive anti-thyroglobulin Abs (TgAbs) and/or anti–thyroid peroxidase (TPOAbs) baseline was significantly higher in group that thyroiditis (3/4) compared did not develop (3/62; P = 0.002). There no significant differences other clinical variables between groups. than during TgAbs TPOAbs associated development irAEs, pneumonitis, colitis, or skin reactions. Our real-world data showed an irAE frequently before treatment. findings indicate evaluating treatment may help identify high risk thyroidal important benefit.